Views & Analysis The biggest pharma stories of 2016 so far The top 10 pharma milestones of the year to date.
Views & Analysis After 2015's ‘breakthrough’ year for pharma approvals, will ... Roche's MS drug is among major drugs still to come in 2016.
Views & Analysis NICE plans to charge for appraisals – but pharma wants refor... Will NICE introduce fees for pharma companies' TAs from next year?
Views & Analysis Fighting diminishing HCP access Predictive sales analytics can help pharma reps make limited time with healthcare professionals count.
Views & Analysis Saving the jewel in the crown of ‘UKplc’: Brexit's impact on... Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.
Views & Analysis Access to cancer drugs: planning for every outcome New UK oncology drug assessment procedures examined.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
